A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

START-lung is an international, multicentre, single-arm phase II trial. Protocol treatment consists of tarlatamab administered as an intravenous infusion until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first. The primary objective of the trial is to assess the clinical efficacy of tarlatamab, in terms of 12-month OS rate, in patients with ES-SCLC and ECOG PS 2 who have previously received only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition and whose disease has progressed.

Trial Details

NCT ID
NCT07203053
Phase
PHASE2
Sponsor
ETOP IBCSG Partners Foundation
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tarlatamab
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Bordeaux, France|44.84124,-0.58046
  • Lyon, France|45.74906,4.84789
  • Marseille, France|43.29695,5.38107
  • Athens, Greece|37.98376,23.72784

Key Eligibility Criteria

  • Histologically or cytologically confirmed ES-SCLC.
  • Previous treatment with only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition for SCLC.
  • Patients treated with a platinum-etoposide doublet chemotherapy for prior limited stage (LS)-SCLC may be eligible for the study if the disease has …
  • Progressive disease on or after the first-line treatment for SCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →